Key result
In patients with moderate pre-dialysis chronic kidney disease and low cardiovascular risk, the presence of late gadolinium enhancement was not associated with adverse cardiovascular outcomes.
Why the study?
Myocardial abnormalities occur in early CKD, but data defining the prevalence, patterns, and clinical implications of LGE-CMR in CKD were lacking.
Does the presence of late gadolinium enhancement on cardiac magnetic resonance imaging predict adverse cardiovascular outcomes in patients with pre-dialysis chronic kidney disease?
Population
159 pre-dialysis CKD stage 2-5 patients attending specialist renal clinics in the UK
Comparison
Presence of LGE (LGEpos) vs absence of LGE (LGEneg) on CMR
Design
Cohort study with blinded image assessment
Follow-up
Median 3.8 years [1.04-11.59]
Authors
Loading...
Hypothesis-generating for LGE in pre-dialysis CKD; should not yet inform clinical risk stratification without larger validation.
Cohort (n=159)
Blinded outcome assessment
No
Does the presence of late gadolinium enhancement on cardiac magnetic resonance imaging predict adverse cardiovascular outcomes in patients with pre-dialysis chronic kidney disease?
Absolute Event Rate: 12.7% vs 4.8%
In a selected cohort of patients with moderate pre-dialysis chronic kidney disease and low cardiovascular risk, late gadolinium enhancement was prevalent but did not predict adverse cardiovascular outcomes.
Price et al. (2019) conducted a cohort in Pre-dialysis chronic kidney disease (n=159). Late gadolinium enhancement (LGE) vs. Absence of LGE was evaluated on Adverse cardiovascular outcomes. In patients with moderate pre-dialysis chronic kidney disease and low cardiovascular risk, the presence of late gadolinium enhancement was not associated with adverse cardiovascular outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: